Skip to content

Clinical trials

Observational Colitis, Ulcerative trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Colitis, Ulcerative Phase: Observational Country / region: United States Clear all

112 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20021
20034
20041
20053
20063
20073
20096
20105
20115
20123
20134
20142
20157
20165
20173
20187
20193
20204
20218
20225
20237
20244
202510
20265

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed51
Recruiting20
Terminated10
Active, not recruiting9
Unknown status7
Enrolling by invitation6
Withdrawn5
Suspended3
Not yet recruiting1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Mayo Clinic6
University of North Carolina, Chapel Hill5
Johns Hopkins University4
Beth Israel Deaconess Medical Center3
Icahn School of Medicine at Mount Sinai3
Takeda3
University Hospitals Cleveland Medical Center3
University of California, Los Angeles3
University of Wisconsin, Madison3
Alimentiv Inc.2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Colitis, Ulcerative112
Crohn Disease72
Inflammatory Bowel Diseases62
Irritable Bowel Syndrome12
Celiac Disease11
Psoriasis8
Colonic Neoplasms7
Multiple Sclerosis7
Colorectal Neoplasms6
Lymphoma6

Trials

Showing 1 to 25 of 112. Each trial links to its page on Pharma Observatory.

12 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.